AstraZeneca Plc and Bristol Myers Squibb have engaged in preliminary discussions regarding a potential combination that could result in a pharmaceutical giant valued at nearly $400 billion. The Financial Times first reported these talks, though Reuters was unable to confirm if they are ongoing. Such a deal would face considerable regulatory scrutiny, particularly from U.S. antitrust authorities under President Donald Trump's administration, which has prioritized domestic investments and expanding U.S. manufacturing. Despite AstraZeneca's prior plans for a direct U.S. listing to capitalize on stronger valuations, this merger would entail a UK-based company acquiring a major U.S. pharmaceutical firm.
The potential merger faces significant antitrust challenges due to substantial overlaps in the companies' cancer drug portfolios. Oncology treatments constituted approximately $25 billion of AstraZeneca's sales in 2025, representing nearly half of its total revenue, while Bristol Myers' oncology drugs accounted for over 40% of its sales in the first half of 2026. Specifically, the two companies' cancer immunotherapies are direct competitors. Andre Barlow, an antitrust lawyer at DBM Law Group, indicated that a Trump FTC would likely scrutinize the merger and demand meaningful divestitures if there are significant overlaps in existing drugs and late-stage pipeline assets. He also noted that there is bipartisan support for scrutinizing pharma deals, suggesting broader questions about product bundling and future innovation would also be raised.
Bristol Myers Squibb has been pursuing smaller acquisitions to bolster its drug pipeline as it anticipates declining sales for older medications, some of which are nearing patent expiration. Its top-selling products, cancer immunotherapy Opdivo and blood thinner Eliquis, could lose patent protection by 2028. In 2019, Bristol Myers acquired Celgene for about $80 billion, a deal that, according to Barlow, saw the Trump FTC necessitate the divestiture of the psoriasis treatment Otezla for $13.4 billion. AstraZeneca, on the other hand, has experienced robust growth, driven by strong demand for its cancer and rare-disease drugs, with its share price more than quadrupling during CEO Pascal Soriot's 14-year tenure.
